Apr 15, 2007 | NEWS
deCODE genetics, Inc. (Nasdaq:DCGN) today announced the launch of deCODE T2™, a novel DNA-based reference laboratory test for the first common and well-validated genetic risk factor for type 2 diabetes (T2D). deCODE believes this test may provide an important means to...
Apr 1, 2007 | NEWS
First publication of genome-wide association study leveraging deCODE’s population approach; Finding to be integrated into deCODE’s DNA-based diagnostics program A team of deCODE scientists, along with academic colleagues from the United States, Iceland, Spain and the...
Aug 14, 2006 | NEWS
deCODE genetics (Nasdaq:DCGN) today announced that it has begun enrolling patients in its Phase I clinical development program for DG051, the company’s follow-on developmental compound for the prevention of heart attack. The ascending-dose, double-blind, randomized,...
Jun 29, 2006 | NEWS
June 29, 2006 deCODE genetics (Nasdaq: DCGN) today announced that it has submitted an investigational new drug application (IND) to the US Food and Drug Administration (FDA) for DG051, the company’s follow-on investigational compound for the prevention of heart...
Jun 24, 2006 | NEWS
June 24, 2006 deCODE genetics (Nasdaq:DCGN) today announced positive results from its preliminary Phase II clinical trial (Phase IIa) of Cephalon Inc.’s (Nasdaq: CEPH) CEP-1347 in asthma. Data on patients receiving active drug in the trial were consistent with a...
Jun 20, 2006 | NEWS
June 20, 2006 A population-based study by a team of deCODE scientists and colleagues at Iceland’s National University Hospital published today provides a detailed look at the impact of a gene variant on risk of breast cancer. The variant is within a gene called BARD1...
